Dr. Tomasz Zastawny serves as Vice President of Drug Development, responsible for pre-clinical and clinical development of Amrita Therapeutics biopharmaceutical products and therapeutic devices. This includes setting up and supporting Amrita's evolving R&D structures, operations and regulatory processes, vendor management and oversight of cross-functional teams.
With nearly a quarter century of research experience in the fields of pharmaceutical clinical operations, project managment /operations, and clinical science, Tomasz brings a wealth of relevant knowledge and experience to Amrita Therapeutics that is invaluable for the successful clinical development of lead oncology programs AT-01C, AT-01D and the SMAR1 biomarker for precision medicine.
His educational experience includes a Ph.D in Medical Sciences, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, where he later served as Professor and Head of the Genotoxicology Department as well as Associate Profressor, Department of Clinical Biochemistry. Additional qualifications include a D.Sc. in Biochemistry, Polish Academy of Science, Warsaw, Poland, M.Sc in Biochemistry, University of Lodz, Department of Biochemistry in Lodz, Poland, and a Graduate Certificate, Strategic Management in Business, University of Banking, Poznan, Poland. He is a frequent lecturer and panelists at leading biopharma conferences, and has authored over 80 articles in peer reviewed journals, book chapters, and conference presenttaions relating to biopharma R&D and clinical research.